Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that its investigational liver therapy efimosfermin, a once-monthly FGF21-based injection, has received US FDA Breakthrough Therapy designation and EMA PRIME status for treating metabolic dysfunction-associated steatohepatitis (MASH). These regulatory designations are intended to speed development of medicines with strong early evidence in serious diseases.
Phase II data in MASH patients with moderate to advanced (F2/F3) and cirrhotic (F4) fibrosis showed fibrosis improvement and MASH resolution versus placebo, with a generally well‑tolerated safety profile and mostly mild, transient gastrointestinal side effects. Efimosfermin is now in phase III ZENITH-1 and ZENITH-2 trials in F2/F3 patients, with additional phase III studies in F4 MASH planned this year.
MASH is described as a chronic, progressive liver disease affecting up to 5% of the global population and a leading cause of liver transplant in the US and Europe, with limited liver‑specific treatments and no approved options for cirrhotic MASH. GSK highlights efimosfermin’s potential to directly target liver fibrosis and positions it as part of a broader hepatology pipeline in MASH, chronic hepatitis B and alcohol‑associated liver disease.
GSK plc, through its subsidiary TESARO, reports a procedural update in ongoing litigation with AnaptysBio over rights to the cancer drug dostarlimab (Jemperli). The Delaware Chancery Court granted a motion by AnaptysBio to dismiss TESARO's claim for anticipatory breach. GSK notes that the ruling does not address the core contractual dispute and does not affect TESARO's remaining claim for declaratory judgment, which it plans to pursue at trial. Jemperli, the brand name for dostarlimab, is approved in over 35 countries for certain endometrial cancers, and GSK reports significant growth driven by label expansions and an ongoing clinical program in additional cancer types.
GSK plc reported a routine executive share transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account. The transaction covered 8.572 ADS at a price of $55.7000 per ADS on 2026-04-22 on the New York Stock Exchange.
GSK plc reports that, on 22 April 2026, it repurchased 965,671 ordinary shares of 31¼ pence each under its existing buyback programme, acting through BNP Paribas. The shares were bought at a volume-weighted average price of 2,081.15p, with prices ranging from 2,073.00p to 2,093.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 21,487,192 ordinary shares. After this transaction, it holds 261,378,286 shares in treasury and has 4,054,820,748 ordinary shares in issue, giving a total of 4,054,820,748 voting rights. Treasury shares represent 6.45% of voting rights, as confirmed under DTR 5.5.1R.
GSK plc reports repurchasing 335,000 ordinary shares on 21 April 2026 as part of its existing buyback programme, using BNP Paribas as broker. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,074.00p and 2,130.00p, at a volume‑weighted average price of 2,103.08p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 260,412,615 shares in treasury and has 4,055,786,419 ordinary shares in issue excluding treasury shares, which equals the total number of voting rights. Treasury shares represent 6.42% of voting rights under DTR 5.5.1R.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 20 April 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,134.00p and 2,156.00p per share, with a volume‑weighted average price of 2,141.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 20,186,521 ordinary shares under this programme. After this transaction, GSK will hold 260,077,615 shares in treasury and have 4,056,121,419 ordinary shares in issue, which is also the total number of voting rights. GSK states that, following this purchase, treasury shares represent 6.41% of voting rights.
GSK plc reports that Chief People Officer Diana Conrad acquired 65.267 American Depositary Shares at $58.3499 per ADS on 13 April 2026. The ADSs were acquired through reinvestment of dividends paid on 9 April 2026 on shares held within a GSK pension plan.
GSK plc received approval in China for Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
The decision by China’s National Medical Products Administration followed priority review and Breakthrough Therapy Designation for the regimen. It is the only anti-BCMA option approved in second line and beyond multiple myeloma in China, and the only fully outpatient anti-BCMA therapy, allowing 30-minute infusions without hospitalisation.
The DREAMM-7 phase III trial showed the Blenrep combination nearly tripled median progression-free survival to 36.6 months versus 13.4 months for a daratumumab-based triplet, and reduced the risk of death by 42%. Three-year overall survival was 74% for the Blenrep regimen versus 60% for the comparator, with safety broadly consistent with known profiles and manageable eye-related side effects.
GSK plc reports that on 17 April 2026, it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,115.00p to 2,137.00p per share, with a volume‑weighted average price of 2,126.15p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 19,856,521 ordinary shares. After this transaction, it holds 259,747,615 shares in treasury and has 4,056,451,419 shares in issue (excluding treasury shares), which is also the total number of voting rights. Treasury shares represent 6.40% of voting rights.
GSK plc reports that, acting through BNP Paribas, it purchased 330,000 ordinary shares of 31¼ pence each on 16 April 2026 as part of its existing share buyback programme. The shares were bought at prices between 2,116.00p and 2,136.00p, with a volume‑weighted average price of 2,125.06p, and will be held as Treasury shares.
GSK states that since 17 February 2026 it has purchased 19,526,521 ordinary shares under this programme. Following the latest transaction, it holds 259,417,615 ordinary shares in treasury and has 4,056,773,154 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights in the company.
The company confirms that, in line with DTR 5.5.1R, the percentage of voting rights attributable to the ordinary shares held in treasury is 6.39%. Investors may use the updated total voting rights figure of 4,056,773,154 as the denominator when assessing whether disclosure thresholds under the Financial Conduct Authority’s rules are met.